Tageszeitungen (Symbolbild).
Quelle: - pixabay.com:
Google
Businesswire  | 
aufrufe Aufrufe: 69

BIOQUAL Presents Unaudited Financial Results for First Quarter of Fiscal Year 2026

BIOQUAL, Inc. www.bioqual.com BIOQ(Pink Limited):

play Anhören
share Teilen
feedback Feedback
copy Kopieren
newsletter
font_big Schrift vergrößern
Bioqual 38,50 $ Bioqual Chart -0,03%
Zugehörige Wertpapiere:

Three Months Ended

August 31,

 

2025

 

2024

 

Revenue

9,855,399

 

11,770,482

 

 

Loss Before Income Tax

(343,432

(931,825

 

Net Loss

(248,832

(675,325

 

Basic Earnings per Share of Common Stock

(0.28

(0.76

 

Diluted Earnings per Share of Common Stock

(0.28

(0.76

 

Weighted Average

 

 

 

 

 

 

Number of Shares Outstanding

 

 

 

 

 

 

For Basic Earnings Per Share

 

894,416

 

 

894,416

 

 

Weighted Average

 

 

 

 

 

 

Number of Shares Outstanding

 

 

 

 

 

 

For Diluted Earnings Per Share

 

893,989

 

 

894,405

 

For more detail related to the fiscal year 2026 unaudited first quarter results, please visit our web site at www.bioqual.com.

Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. The forward-looking statements are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including risks relating to the ability to continue to extend current government contracts; the Company’s ability to obtain new government or commercial contracts; continued demand for the use of animal models in scientific research; the Company’s ability to obtain sufficient numbers of animal models; the availability of adequate numbers of employees; the Company’s ability to perform under its contracts in accordance with the requirements of the contracts; the actual costs incurred in performing the Company’s contracts and its ability to manage its costs, including its capital expenditures; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing/capital sources to the Company.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251021281728/en/

Für dich aus unserer Redaktion zusammengestellt

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.


Weitere Artikel des Autors

Themen im Trend